Mukul Verma 11/30/22 Mukul Verma 11/30/22

Israeli biotech company begins trial for cancer immuno-oncology solution

Nectin's product, NTX1088, blocks the harmful overexpression of PVR proteins, which occurs in tumors caused by lung, breast, throat and other cancers.

Mukul Verma 11/30/22 Mukul Verma 11/30/22

Nectin Announces Extended Series A Financing to Over $25M and Start of Patient Dosing in Phase 1 Clinical Trial of First-in-Class Immunotherapy for Treatment of Patients with Advanced Solid Tumors

Mukul Verma 3/7/22 Mukul Verma 3/7/22

Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy

Mukul Verma 2/17/22 Mukul Verma 2/17/22

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers

Mukul Verma 5/26/21 Mukul Verma 5/26/21

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers--

Mukul Verma 4/30/21 Mukul Verma 4/30/21

Mereo and Focus Fund Announce Etigilimab partnership with MD Anderson

Study to be Conducted at The University of Texas MD Anderson Cancer Center

Mukul Verma 10/20/20 Mukul Verma 10/20/20

MD Anderson Brings Underdogs into the Fight Against Cancer with Cancer Focus Fund

Mukul Verma 10/20/20 Mukul Verma 10/20/20

Cancer Focus Fund and MD Anderson Launch Investment Fund to Underwrite Promising Cancer Therapies in Clinical Trials

Cancer Focus Fund and MD Anderson launch $50 million investment fund to support promising investigational cancer therapies in early-stage clinical trials. Access to MD Anderson minds and clinical facilities will help advance novel candidates.